Masimo Co. (NASDAQ:MASI) Receives $145.33 Consensus Target Price from Brokerages

Masimo Co. (NASDAQ:MASI) has been given an average rating of “Moderate Buy” by the seven brokerages that are currently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $145.33.

A number of research firms have recently commented on MASI. Piper Sandler reaffirmed an “overweight” rating on shares of Masimo in a research note on Friday. BTIG Research upped their target price on Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research note on Friday, September 20th.

Masimo Trading Down 0.2 %

Shares of NASDAQ MASI opened at $143.73 on Friday. The business’s 50 day moving average is $126.30 and its two-hundred day moving average is $125.07. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.09 and a quick ratio of 1.15. Masimo has a 1-year low of $75.36 and a 1-year high of $153.93. The stock has a market capitalization of $7.64 billion, a P/E ratio of 97.78 and a beta of 0.99.

Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.09. Masimo had a return on equity of 14.07% and a net margin of 3.94%. The company had revenue of $496.30 million for the quarter, compared to analysts’ expectations of $493.92 million. During the same period in the previous year, the firm posted $0.62 earnings per share. The firm’s revenue for the quarter was up 9.0% on a year-over-year basis. As a group, research analysts expect that Masimo will post 3.88 EPS for the current year.

Institutional Trading of Masimo

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Allspring Global Investments Holdings LLC lifted its holdings in shares of Masimo by 5,340.9% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,394 shares of the medical equipment provider’s stock valued at $319,000 after purchasing an additional 2,350 shares during the last quarter. Cardinal Capital Management lifted its holdings in shares of Masimo by 19.9% during the 3rd quarter. Cardinal Capital Management now owns 18,517 shares of the medical equipment provider’s stock valued at $2,469,000 after purchasing an additional 3,077 shares during the last quarter. Kapitalo Investimentos Ltda purchased a new stake in shares of Masimo during the 3rd quarter valued at $242,000. NBC Securities Inc. raised its stake in Masimo by 47.1% in the 3rd quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 73 shares during the last quarter. Finally, Exchange Traded Concepts LLC raised its stake in Masimo by 17.4% in the 3rd quarter. Exchange Traded Concepts LLC now owns 12,550 shares of the medical equipment provider’s stock worth $1,673,000 after acquiring an additional 1,862 shares during the last quarter. Hedge funds and other institutional investors own 85.96% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.